NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
Al B Benson 3rd, Michael I D'Angelica, Daniel E Abbott, Thomas A Abrams, Steven R Alberts, Daniel Anaya Saenz, Chandrakanth Are, Daniel B Brown, Daniel T Chang, Anne M Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R Kate Kelley, Robin Kim, Manisha Palta, James O Park, Vaibhav Sahai, Tracey Schefter, Carl Schmidt, Jason K Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G Gary Tian, Jean-Nicolas Vauthey, Alan P Venook, Andrew X Zhu, Karin G Hoffmann, Susan Darlow, Al B Benson 3rd, Michael I D'Angelica, Daniel E Abbott, Thomas A Abrams, Steven R Alberts, Daniel Anaya Saenz, Chandrakanth Are, Daniel B Brown, Daniel T Chang, Anne M Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R Kate Kelley, Robin Kim, Manisha Palta, James O Park, Vaibhav Sahai, Tracey Schefter, Carl Schmidt, Jason K Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G Gary Tian, Jean-Nicolas Vauthey, Alan P Venook, Andrew X Zhu, Karin G Hoffmann, Susan Darlow
Abstract
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.
Copyright © 2017 by the National Comprehensive Cancer Network.
Figures
Source: PubMed